P/B
3,9
Neurocrine Biosciences
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
$14.3B
Market Cap • 9/28/2026
1992
(34 years)
Founded
1996
(30 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
4,2
P/EBITDA
17
P/OCF
15,9
P/FCF
16,4
P/E
20,6
BVPS
35,7
EPS
6,8
Market Cap
Market Cap
14,3B
EV
14,3B
EV/Revenue
4,2
EV/EBITDA
17
EV/EBIT
18
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,9%
Total Yield
-0,9%
Payout
0%
Retained Earnings
724M
Profitability
Gross Margin
98%
EBITDA Margin
25%
EBIT Margin
23,6%
Net Margin
20,9%
D&A/EBITDA
1,9%
R&D/Revenue
34,7%
Capex/Revenue
0,8%
Capex/D&A
58,6%
Capex/OCF
3,1%
SBC/OCF
26,1%
% PPE
10%
% Goodwill
9,3%
ROE
22,1%
ROIC
18,5%
Growth
CAGR Revenue 5Y
26,7%
CAGR Op. Income 5Y
45,5%
CAGR Net Income 5Y
14,1%
CAGR EPS 5Y
12,9%
CAGR OCF 5Y
28,1%
Leverage
N.D./EBITDA
0
Debt/Equity
0%
Current Ratio
1,9
Quick Ratio
1,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!